Friday, 11 June 2021

Porcine Reproductive and Respiratory Syndrome Vaccine Market Analysis-2027

 

Porcine Reproductive and Respiratory Syndrome Vaccine Market, By Product Type (Modified Live Virus Vaccine, Inactivated Vaccine, and Subunit Vaccines), By Route of Administration (Intramuscular and Intradermal), By Virus Genotype (Type I and Type II), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlooks, and Opportunity Analysis, 2019-2027

Porcine reproductive and respiratory syndrome (PRRS) is a viral disease which causes various reproductive problems such as late term abortions, infertility, weak and still born piglets in sows and respiratory problems like labored breathing, fever and pneumonia in pigs of all age group. Porcine reproductive and respiratory syndrome virus (PRRSV) is contagious which can be transmitted by infectious aerosols or direct contact.

Porcine reproductive and respiratory syndrome vaccines prevent the pigs from acquiring this syndrome. The vaccine is developed on the basis of two genotypes of the virus; Type I (European) and Type II (North American) and can be administered through intramuscular route or intradermal route.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3285

Global Porcine Reproductive and Respiratory Syndrome Vaccine Market Dynamics

An increasing demand for pork meat is expected to propel the market growth over the forecast period. According to the U.S Department of Agriculture - Foreign Agricultural Service (USDA – FAS), 2017, among the total meat consumption nearly 40.4% of pork meat is consumed globally.

Moreover, significant economic losses to swine producers caused by the porcine reproductive and respiratory virus is expected to propel the market growth. For instance, according to the statistics presented in the North American PRRS Symposium held in November 2019, an around 62% out of total economic loss was reported in the pork meat production market, which is US$ 581 million, has occurred in the growing period of the pigs due to the porcine reproductive and respiratory virus.

Global Porcine Reproductive and Respiratory Syndrome Vaccine Market - Regional Insights

North America accounted for the largest market share in 2018 owing to launch and approval of new vaccines for the porcine reproductive and respiratory syndrome in the region. For instance, in June 2018, Elanco Animal Health, a division of Eli Lily and Company, introduced a modified live respiratory vaccine, Prevacent PRRS to reduce the porcine reproductive and respiratory syndrome (PRRS), respiratory form, in two weeks or older piglets. Similarly, in 2018, MSD Animal Health launched a needle free device, IDAL 3G, with two injector heads for intradermal vaccination.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/porcine-reproductive-and-respiratory-syndrome-vaccine-market-3285

1The device makes the vaccine administration a safer and less stressful procedure for the pigs and more efficient and convenient for farmers. The device is used to administer vaccines like PORCILIS PRRS, for porcine reproductive and respiratory syndrome virus and PORCILIS PCV ID, for porcine circovirus type 2 simultaneously.

Global Porcine Reproductive and Respiratory Syndrome Vaccine Market - Competitive Landscape

Key players operating in the porcine reproductive and respiratory syndrome vaccine market include Boehringer-Ingelheim GmbH, Zoetis, MSD Animal Health, Bioveta, Phibro Animal Health, Ceva , Ascent Corporation, Agrovet, Winsun Bio, Konipharm, Merck & Co., Inc., Elanco (Eli Lily and Company), and Ringpu (Tianjin) Bio-Pharmacy Co., Ltd.

Moreover, key players in the market are focused on developing new products in order to enhance their market share. For instance, in October 2019, Boehringer-Ingelheim launched Reprocyc ParvoFLEX, a subunit vaccine for the swine fetuses to protect them from the transplacental infections caused by porcine parovirus.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3285

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Bio-identical Hormones Market Size Share Trends Forecast 2026

 

Bio-identical Hormones Market, By Product Type (Estrogen, Progesterone, and Testosterone), By Dosage Form (Tablets and Capsules, Creams and Gels, Injectable, Patches and Implants, and Others), By End User (Hospitals, Clinics, Academics and Research Institutes, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Bio-identical hormones are biochemically engineered hormones that resemble hormones produced by the human body through natural biological processes. Estrogen, progesterone and testosterone are some of the common hormones that are manufactured artificially.

Levels of hormones such as estrogen, progesterone and testosterone in the body are lowered with progression in age, which leads to certain menopausal symptoms in females such as hot flashes, weight gain, and vaginal pain due to sexual intercourse, vaginal dryness, night sweats, mood swings. In men, low testosterone level can cause erectile dysfunction and reduced bone density. Bio-identical hormones are used to treat men and women whose natural hormones levels are low or imbalanced. The bio-identical hormones act as a replacement for natural hormones and increase the hormonal levels in the body. This process is called bio-identical hormone replacement therapy (BHRT). Bio-identical hormones are available in the form of pills, creams, patches, gels, injectables, and implants.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3293

Global Bio-identical Hormones Market – Dynamics

Factors such as increasing geriatric population and females in the menopausal age group are expected to boost the growth of the bio-identical hormones market over the forecast period. For instance, according to an article published in the National Center for Biotechnology Information (NCBI) in November 2019, nearly 1.3 million women become menopausal every year in the U.S and around 75% of the females experience vasomotor symptoms such as hot flashes, palpitations and night sweating due to menopause.

In addition to the aforementioned factors, rising awareness about the bio-identical hormone replacement therapy (BHRT), coupled with increased screening of hormonal deficiency is projected to propel the market growth over the forecast period. For instance, according to a study conducted by researchers from the Obstetrics and Gynecology Department of Kafkas University in January 2019, in Turkey, nearly 432 females out of 926 opted for bio-identical hormone replacement therapy in order to treat their menopausal symptoms.

However, an increased risk of breast cancer in females opting for bio-identical hormone therapy is expected to restrain the market over the forecast period. For instance, according to a study published in The Lancet journal, September 2019, nearly 108,647 postmenopausal women developed breast cancer, from 1992 to 2018, among these approximately 55,575 females were using the hormonal therapy.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/bio-identical-hormones-market-3293

Global Bio-identical Hormones Market – Regional Insights

North America accounted for the largest market share in 2018 owing to launches and approvals of bio-identical hormones in the region. For instance, in September 2018, TherapeuticsMD, Inc., a pharmaceutical company, launched Imvexxy, (estradiol vaginal inserts) in the U.S. Imvexxy is used for treating moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), due to menopause. Moreover, in June 2019, TherapeuticsMD, Inc. announced a license and supply agreement with Theramex, a pharmaceutical company dedicated to women’s health, to commercialize IMVEXXY (estradiol vaginal inserts) and BIJUVA (estradiol and progesterone capsules) outside of the U.S., except in Canada and Israel.

Global Bio-identical Hormones Market – Competitive Landscape

Key players operating in the market are TherapeuticsMD, Inc., BioTE Medical, Defy Medical, Full Life Wellness Center, Neuva Aesthetics, and SottoPelle.

Moreover, key players in the market are focused on developing new products in order to enhance their market share. For instance, in October 2018, TherapeuticsMD, Inc. received U.S. Food and Drug Administration (FDA) approval for its first bio-identical hormone combination therapy of estradiol and progesterone, BIJUVA. The oral capsule is used for treatment of moderate to severe vasomotor symptoms due to menopause in women.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3293

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Diabetic Retinopathy Market Size, Trends, Shares, Insights and Forecast – 2018-2026

 

Diabetic Retinopathy Market, by Disease Type (Proliferative Diabetic Retinopathy and Non-proliferative Diabetic Retinopathy), by Treatment (Anti Vascular Endothelial Growth Factor Therapy and Intraocular Steroid Injection), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Diabetic retinopathy is one of the complications of diabetes, in which blood vessels in the retina gets damaged due to high blood glucose level. Retina is the light sensitive inner lining at the back of the eye. Diabetic retinopathy mostly affects both the eyes. As disease condition progresses, diabetic retinopathy symptoms including fluctuating vision, blurred vision, impaired color vision or sometimes dark and empty areas in vision leads to vision loss. The line of treatment for diabetic retinopathy depending on the disease condition of the patient, may require laser surgery, intraocular injections, and anti (VEFG) vascular endothelial growth factor therapy.

Global Diabetic Retinopathy - Market Dynamics

Increasing incidence of diabetes along with increasing cases of blindness due to diabetes are expected to drive the diabetic retinopathy market growth. According to the International Diabetic Federation report, 2017, around 425 million adults of age group 20 to 79 years are suffering from diabetes. According to the International Agency for the Prevention of Blindness, 2016, one in three people having diabetes have high chances of getting affected by diabetic retinopathy. Moreover, according to the article published in The Lancet, 2018, the annual incidence of diabetic retinopathy ranges from 2.2% to 12.7%, globally.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3313

Moreover, several launches and approvals of new diabetic retinopathy medications are expected to boost growth of the diabetic retinopathy market over the forecast period. For instance, in May 2019, Regeneron Pharmaceutical received the U.S. Food and Drug Administration (FDA) approval for EYLEA, an aflibercept injection for diabetes retinopathy. EYLEA is the only vascular endothelial growth factor (VEGF) inhibitor approved in two dosing options for diabetes retinopathy, allowing doctors to customize treatment as per patient need.

Global Diabetic Retinopathy Market - Regional Insights

On the basis of geography, the global diabetes retinopathy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America accounted for the largest market share in diabetes retinopathy market, owing to high prevalence of diabetic retinopathy in the region. According to the National Health Interview Survey, 2016-17, around 8.6% people have diabetic retinopathy in the U.S.

Europe also exhibits high growth in diabetes retinopathy market due to high prevalence of diabetic retinopathy. According to a report presented by the University of Bonn, 2017, around 17.7% of diabetic patients have showed signs of moderate non-proliferative diabetic retinopathy while around 2% patients are affected by severe non-proliferative diabetic retinopathy in the Europe. Moreover, according to the same source, around 4.1% of adults aged 45 and above are reported to have vision loss due to diabetic retinopathy in the Europe. 

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/diabetic-retinopathy-market-3313

Asia Pacific region is also witnessing lucrative growth in diabetic retinopathy market due to increasing disposable income, large patient pool, and innovation in diagnostic approach and government health insurance policies. According to the journal of Diabetology report 2018, around 80 million people were suffering from diabetes in Asia Pacific region in 2017 and is expected to increase to 151 million by 2045. Furthermore, according to The Union Health Ministry’s first National Diabetes and Diabetic Retinopathy Survey conducted from 2015-2019, around 16.9% of people are suffering from diabetic retinopathy in India.

Global Diabetic Retinopathy Market - Competitive Landscape

Key players operating in the global diabetic retinopathy market include Novartis AG, Regeneron Pharmaceuticals, Bayer Healthcare, Actavis Plc, Alimera Science, Pfizer Inc., Hoffmann-La Roche Ltd, Abbott Laboratories Ltd, Sirnaomics, Glycadia pharmaceuticals, Boehringer Ingelheim, Therapeutics Inc, Ampio pharmaceuticals, Lupin ltd, and others.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3313

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Ephedrine Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

 

Ephedrine Market, By Dosage Form (Tablets, Capsules, and Injections), By Disease Indication (Bronchial Asthma, Spinal Anesthesia induced Hypotension, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Ephedrine is a decongestant and bronchodilator, used to treat bronchospasms caused due to asthma. The medicine reduces the swelling and constricts the blood vessels in the nasal passages which widens the lung airways and allows the patient to breathe easily. Due to the medicine’s central nervous system stimulatory effects, ephedrine is also used extensively during spinal anesthesia in order to prevent intra-operative hypotension. The medicine is available in the form of tablets, capsules and injections.

Global Ephedrine Market – Dynamics

High prevalence of hypotension during spinal anesthesia is expected to propel growth of the ephedrine market over the forecast period. For instance, according to the Columbian Journal of Anesthesiology, 2018, incidences of hypotension during spinal anesthesia ranges from 1.9% to 71% globally. 

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3320

Moreover, launches and approvals of ephedrine products is expected to boost the ephedrine market growth over the forecast period. For instance, in January 2017, Par Pharmaceutical, a subsidiary of Endo International plc, received approval from the U.S. Food and Drug Administration (FDA) for its new ephedrine sulfate injection, CORPHEDRA. The injection will be used to for the treatment of hypotension occurring in the process of spinal anesthesia.  

However, restrictions on ephedrine usage through regulatory authorities is expected to restrain the market over the forecast period. For instance, since 2001, the Government of Canada has authorized ephedrine only as a nasal decongestant with a maximum dosage of 8mg along with 32mg in a 24 hour period.

Global Ephedrine Market – Regional Insights

North America accounted for the largest market share in 2018, owing to launches and approvals of new ephedrine products in the region. For instance, in March 2017, Akorn, Inc., a developer and manufacturer of generics and branded prescription pharmaceuticals, received the U.S. Food and Drug Administration (FDA) approval for its New Drug Application (NDA) for single dose ampule of an ephedrine sulfate injection which is indicated for treating hypotension occurring during spinal anesthesia.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/ephedrine-market-3320

Increasing ephedrine product launches is expected to propel the market growth in the Europe region. For instance, in April 2016, Avadel Pharmaceuticals, formerly known as Flamel Technologies, received approval from the U.S. Food and Drug Administration for Akovaz, an ephedrine sulfate injection, which will be used to treat hypotension occurring during anesthesia.

Moreover, high prevalence of hypotension during spinal anesthesia in Asia Pacific is likely to drive the ephedrine market over the forecast period. For instance, according to a study published in the Indian Journal of Anesthesia, 2018, the cases of mild, moderate, and severe spinal anesthesia induced hypotension was approximately 20%, 35%, and 40% respectively. 

Global Ephedrine Market – Competitive Landscape

Key player operating in the market include Servier, Merck Sharp & Dohme Corp., Amgen Inc., Sanofi S.A., Avadel Pharmaceuticals, GlaxoSmithKline plc, Endo Pharmaceuticals plc, and Akorn Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3320

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Recreational Oxygen Equipment Market To Surpass US$ 9,776.7 Million By 2027

 

Global Recreational Oxygen Equipment Market, by Product Type (Oxygen Concentrator, Oxygen Bar, and Others), by Application (Medical, Athletes/Sport, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  2,832.3 million in 2019, and is expected to exhibit a CAGR of 16.7% during the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing launches of technologies that support medical as well recreational oxygen equipment by increases their effectiveness are expected to drive the market growth. For instance, in February 2019, OxyGo LLC, a provider of portable oxygen concentrator, launched new Bluetooth enabled portable oxygen concentrator (POC), OxyGo FIT Connect. The new platform will allow healthcare providers to improve patient outcomes through a new wireless connectivity platform using Bluetooth technology.  Moreover, in December 2018, Inogen, Inc. launched Inogen Connect, a new wireless connectivity platform for the Inogen One G4, a portable oxygen concentrator.

Browse 26 Market Data Tables and 25 Figures spread through 137 Pages and in-depth TOC on 'Global Recreational Oxygen Equipment Market, by Product Type (Oxygen Concentrator, Oxygen Bar, and Others), by Application (Medical, Athletes/Sport, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3345

Increasing number approvals and launches for recreational oxygen equipment for medical applications are expected to drive the growth of global recreational oxygen equipment market over the forecast period. For instance, in July 2016, Philips’ SimplyGo Mini portable oxygen concentrator conformed to Federal Aviation Administration (FAA) requirements for portable oxygen concentrator (POC) carriage and in-flight use on aircraft. This approval is expected to increase revenue of the SimplyGo Mini portable oxygen concentrator during the forecast period.

Moreover, in September 2017, Oxygen Plus (O+), a private company engaged in development and manufacturing of recreational oxygen, launched its novel innovation in recreational oxygen, The O+ Biggi. The equipment, with its mega-size canister and unique delivery method is engineered and designed to deliver the pure oxygen to boost natural immunity. The O+ Biggi contains more than 180 breaths (7 liters) of pure recreational oxygen for natural energy.

Rising awareness about respiratory care devices among the population in the developed as well as emerging economies are expected to drive demand for recreational oxygen equipment such as oxygen concentrator, which are mainly used in home-care settings. Moreover, rising prevalence of chronic obstructive pulmonary diseases (COPD) among the geriatric population are expected to fuel growth of the market over the forecast period. For instance, according to the World Health Organization (WHO), in 2016, 251 million people globally developed COPD.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/recreational-oxygen-equipment-market-3345

Key Takeaways of the Global Recreational oxygen equipment market:

The global recreational oxygen equipment market is expected to exhibit a CAGR of 16.7% during the forecast period (2019-2027), owing to increasing product launches. For instance, in April 2019, Inogen, Inc. INGN launched its Inogen One G5 portable oxygen concentrator in the U.S. homecare market. The product has is capable of producing large amount of oxygen.

Increasing adoption of inorganic strategies such as acquisition by key players are also expected to drive the growth of the global recreational oxygen equipment market over the forecast period. For instance, in October 2018, NGK Spark Plug Co., a company based in Japan, acquired oxygen-related products business of Chart Industries, Inc.

Major players operating in the global recreational oxygen equipment market include Boost Oxygen, LLC, CAIRE Inc. (AirSep), Chart Industries, DeVilbiss Healthcare LLC, Inogen, Inc., Oxygen Plus, Inc., Pure O2 Ltd, Invacare Corporation, Oxyzens, Philips Healthcare, Zadro Health Solutions, and 2ND Wind Oxygen Bars.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3345

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Thursday, 10 June 2021

Sexual Health Market To Surpass US$ 14.1 Billion By 2027 - Coherent Market Insights

 

Global Sexual Health Market, by Product Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation Drugs, and Others), by Gender (Male and Female), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  10,289.5 million in 2019, and is expected to exhibit a CAGR of 4.2%, during the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Major players in the pharmaceutical industry are focusing on introducing various drugs for treating sexual dysfunction, which is expected to drive growth of the sexual health market. For instance, in 2017, Teva Pharmaceutical Industries Ltd. announced the launch of generic version of Viagra (sildenafil citrate) tablets in the U.S. indicated for the treatment of erectile dysfunction. Moreover, in September 2019, Lupin Limited announced the launch of Sildenafil tablets, a generic version of Pfizer Inc.’s Viagra tablets in the U.S. indicated for the treatment of erectile dysfunction.

Browse 35 Market Data Tables and 31 Figures spread through 167 Pages and in-depth TOC on 'Global Sexual Health Market, by Product Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation Drugs, and Others), by Gender (Male, and Female), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),, and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3364

The sexual health market is expected to witness robust growth owing to increasing initiatives by major players operating in the market. These players are engaged in adoption of inorganic growth strategies such as collaborations and partnerships to distribute their product worldwide, and to increase its consumer base. For instance, in May 2014, Sanofi entered an acquisition agreement with Eli Lilly and Company to acquire the rights from the Eli Lilly and Company to apply for regulatory approval for the nonprescription Cialis (OTC) in the U.S., Europe, Canada and Australia.

Moreover, increasing approval of drugs for improving sexual health is expected to drive the global sexual health market growth during forecast period. For instance, in March 2019, VIVUS, Inc., a biopharmaceutical company, received approval from the Ministry of Health of the Russian Federation for its Avanafil tablet (with strength of 50 mg, 100 mg and 200 mg tablets) for treatment of erectile dysfunction (ED). The product is also approved in Jordan, Saudi Arabia, Turkey and the United Arab Emirates market.

Key Takeaways of the Global Sexual Health Market:

The global sexual health market is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027) owing to increasing drug launches for the treatment of sexual dysfunction. For instance, in June 2019, Novitium Pharma LLC receive U.S. FDA approval for its Sildenafil for Oral Suspension, 10mg/mL, (a generic of Pfizer’s Revatio).

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/sexual-health-market-3364

Increasing clinical trials by key players for developing novel treatment option for treating sexual dysfunctions is expected to drive the global sexual health market growth over the forecast period. For instance, in July 31, 2019, Futura Medical Developments Ltd. initiated phase 3 clinical trial to demonstrate the efficacy of various doses of MED2005 (Glyceryl Trinitrate (GTN)) for the treatment of erectile dysfunction, and to evaluate the long-term efficacy and safety (12 months) of MED2005. The study is estimated to complete in October 1, 2020.

Major players operating in the global sexual health market include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3364

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Microsclerotherapy Treatment Market Size Share Trends Forecast 2026

 

Global Microsclerotherapy Treatment Market Restraints

Factors such as side effects and high treatment costs are expected to restrain the global Microsclerotherapy Treatment Market growth. According to the Journal of Phelbolymphology (2017), around 1-10% patients reported matting and residual pigmentation as complications post microsclerotherapy treatment. The treatments are expensive, ranging from, US$ 600 to US$ 1,200, and the cost is dependent upon the size of the vein and at least 2 to 6 treatment sessions are required with the interval of 4 to 6 weeks. The procedure is a little painful while compression bandage is to be worn post operation for several weeks which can be uncomfortable to the patients.

Microsclerotherapy is the method used for the treatment of telangiectasia, which is a condition where broken blood vessels near the surface or mucous membrane appears as pink or red lines on the skin surface. Genetic and environmental factors contribute to telangiectasia. Other factors that could cause telangiectasia are aging, pregnancy, rosacea, overexposure to sunlight, and varicose veins. There is no cure for this disorder, however, can be controlled by microsclerotherapy.

Microsclerotherapy involves injecting a solution called 'sclerosant' using microneedles. The process involves the injection of sclerosant in the affected veins, which destroys the endothelium, it triggers thrombosis followed by fibrosis and this results in the closing of the vessel. Sclerosant such as hypertonic saline solution, polidocanol, tetradecyl sulphate, and chromated glycerin are used in microsclerotherapy.

Some of the key manufacturers operating in the global microsclerotherapy treatment market are Surgimedix, Inc. (microneedles), Merz Pharma GmbH & Co. KGaA  (Polidocanol), QOL Medical LLC (Ethanolamine oleate), Mckesson Corporation (Sotradecol), Kreussler, Inc. (Compression bandage), Provensis, ltd (Varithena), STD Pharmaceuticals Product Ltd. (Fibrovein injections), Medtronic plc (microneedle), Teleflex incorporated Vascular Solutions (Smartneedle vascular access system), and Boston Scientific Corporation (Interject).

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3372

Microsclerotherapy Treatment Market Drivers-

Leading manufacturers are indulged in the development and commercialization of new sclerosants which would be used in the treatment of varicose veins such as hypertonic saline, sodium tetradecyl sulphate, and polidocanol. For instance, Medtronic Plc launched a new product, Venaceal closure system in U.S., in November 2015. The new product is non-invasive and uses a proprietary medical adhesive instead of a sclerosant to seal the varicose veins and is effective for patients suffering from varicose veins by eliminating the need for anesthesia, several injections, and use of compression stockings post operation, thus reducing the disadvantages caused by using sclerosants.

Moreover, in 2014, BTG international Inc. launched varithena (polidocanol) which decreases the symptoms, appearance of varicose veins as well as achiness, itching, and swelling of the veins. Furthermore, manufacturers are also focused on inorganic growth strategies such as mergers and acquisitions. For instance, in August 2019, Boston Scientific acquired BTG International, Inc as BTG manufactures and commercialize products used in minimally invasive treatments used for targeting cancer and other vascular diseases.

According the National Center for Biotechnology Information (NCBI), 2019, 41% people in the U.S. suffer from varicose veins and around 41% of women population and 50% of the men population all over the world, over the age of 50 have telangiectasia. According to NCBI, 2018, lower limb varicose veins are very common and over 10 – 30% of the world wide population suffers from telangiectasia. During the onset of periods and pregnancy, most of the women are prone to telangiectasia. Other reasons are standing and sitting for long periods of time, sitting cross legged, obesity, and others. High incidence of telangiectasia is expected to boost the global microsclerotherapy treatment market growth in the near future.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/microsclerotherapy-treatment-market-3372

Global Microsclerotherapy Treatment Market Regional Analysis-

Highest incidences of telangiectasia has been recorded in the Western Countries like Europe, America and Australia and this disorder is most commonly observed in females as compared to males. According to the International Journal of Pharmaceutical Sciences and Research, (2018), High prevalence of varicose veins has been recorded in U.S, Europe and some parts of Australia. According to the same source, one third of the population worldwide is suffering from varicose veins, out of which, around 73% females (especially during pregnancy) and 56% males are suffering from varicose veins.

Most of the manufacturer’s headquarters are located in U.S. and Europe like QOL Medical LLC, Mckesson Corporation, Kreussler, Inc, and Teleflex Incorporated and Boston Scientific Corporation. Therefore, introduction of existing as well as new treatment options across North America and Europe is expected to drive the global microsclerotherapy treatment market growth over the forecast period.

Global Microsclerotherapy Treatment Market Key Players-

Key players operating in the global microsclerotherapy treatment market are Surgimedix, Inc., Merz Pharma GmbH & Co. KGaA, QOL Medical LLC, McKesson Corporation, Kreussler, Inc., Provensis, ltd, STD Pharmaceuticals Product Ltd., Medtronic plc, Teleflex Incorporated, and Boston Scientific Corporation.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3372

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Endovenous Laser Therapy Market Size, Trends, Shares, Insights and Forecast – 2018-2026

 

Endovenous laser therapy (ELT) closes and shrinks the varicose vein and causes scar tissue within the vessel in order to seals off the vein and promote blood flow through other nearby veins.

The global Endovenous Laser Therapy Market is estimated to account for US$ 329.3 Mn in terms of value and is estimated to reach US$ 591.1 Mn by the end of 2027.

Global Endovenous Laser Therapy Market: Drivers

Increasing adoption of endovenous laser ablation therapy is expected to propel growth of the global endovenous laser therapy market over the forecast period. Endovenous laser ablation therapy is a minimally invasive procedure that makes use of catheters, lasers, and ultrasound to treatment of varicose veins. The procedure requires less time (around an hour) and one small incision. Moreover, the recovery time of patient is also low. These advantages boost adoption of endovenous laser ablation therapy, thereby propelling growth of the market.   

Global Endovenous Laser Therapy Market: Opportunities

Increasing prevalence of obesity is expected to offer lucrative growth opportunities for players in the global endovenous laser therapy market as the condition is a high risk factor for varicose veins. For instance, according to MedAlertHelp.org, over 1.9 billion adults were reported as overweight worldwide. 

Global Endovenous Laser Therapy Market: Restraints

Unfavourable reimbursement scenario in some economies is expected to hinder growth of the global endovenous laser therapy market. For instance, in France, only radiofrequency is reimbursed and not endovenous laser ablation therapy.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3377

Key Takeaways:

The diode lasers segment in the global endovenous laser therapy market was valued at US$ 201.3 Mn in 2018 and is expected to reach US$ 394.9 Mn by 2027 at a CAGR of 7.6% during the forecast period. Diode lasers are used in several endovenous laser systems which is supporting growth of the segment. For instance, VenaCure EVLT 1470 Pro manufactured by AngioDynamics uses high-performing diode laser

The ambulatory surgical centers segment held dominant position in the global endovenous laser therapy market in 2018, accounting for 35.7% share in terms of value, followed by hospitals and specialized clinics, respectively.

Ambulatory surgical centers perform outdoor patient surgeries for which overnight patient admission is not necessary. These type of centers save time as well as costs which is expected to support growth of the segment over the forecast period.       

The North America region held dominant position in the global endovenous laser therapy market in 2018, accounting for 42.4% share in terms of value, followed by Europe and Asia Pacific, respectively.

Factors such as presence of key players in the region, and product launches is expected to support growth of the region over the forecast period. For instance, AngioDynamics, a provider of endovenous laser therapy products is based in the U.S.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/endovenous-laser-therapy-market-3377

Market Trends

In countries such as the U.S., endovenous laser therapy for varicose veins is majorly performed in clinics rather than hospitals in order avoid long-time waiting in big hospital settings, which is why physicians are rapidly adopting laser therapy systems.

In Denmark, prior authorization for using endovenous laser ablation is not required and all patients are covered through state health insurance.

Global Endovenous Laser Therapy Market: Competitive Landscape

Major players operating in the global endovenous laser therapy market include, AngioDynamics, Inc., Candela Corporation, Dornier MedTech GmbH, Alma Lasers Ltd., Alna-Medicalsystem GmbH, LSO Medical, Wontech Co., Ltd., Intros Medical Laser GmbH, and Energist Ltd.

Global Endovenous Laser Therapy Market: Key Developments

October 2019: AngioDynamics, Inc. acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform

May 2019: Candela Corporation partnered with The Vascular Birthmarks Foundation and E.V.A. Clinic to provide pro-bono laser treatments

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3377

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Flavoxate Hydrochloride Tablets Market Size Share Trends Forecast 2026

 

Flavoxate Hydrochloride Tablets Market, By Medicine Type (Branded and Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Middle East, Asia Pacific, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Flavoxa­­te hydrochloride is a muscle relaxant with urinary antispasmodic properties. Flavoxate binds to the muscarinic receptors which suppresses micturition reflex. It helps in modifying micturition center in the brain stem by increasing capacity of the urinary bladder. Therefore, this provides relief from dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence. Manufacturers such as Epic Pharma LLC, Perrigo Company PLC, Incepta Pharmaceuticals Ltd., Recordati S.p.A, and others offer generic flavoxate hydrochloride tablets in the market.

Global Flavoxate Hydrochloride Tablets Market Drivers

Key players are focusing on manufacturing of drugs in the global flavoxate hydrochloride tablets market. Several generic players have launched their products after the patent expiration of Urispas in the year 2004, manufactured by Janssen Pharmaceuticals, Inc. For instance, companies such as Paddock Laboratories LLC and Epic Pharma LLC launched generic products for Urispas, which are cheaper than branded products in the year 2004 and 2011, respectively.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3384

Increasing incidence of lower urinary tract dysfunction such as prolonged micturition, incomplete bladder emptying, and others are expected to support growth of the market. For instance, according to a review article by Investigative and Clinical Urology, 2017, globally, around 10% of the geriatric population is suffering from urine incontinency while it is estimated to reach 20% by 2050. According to the same source, in South Korea, in population aged 70 years above, 48% of men and 12% of women are expected to suffer from detrusor contractile dysfunction in 2017. As per the Central Medicare and Medicaid Services (CMS), U.S., around US$ 8,800 million of flavoxate hydrochloride tablets have been consumed in the year 2017 by patients in U.S. suffering from insomnia. These factors are expected to support the global flavoxate hydrochloride tablets market growth over the forecast period.

Global Flavoxate Hydrochloride Tablets Market Restraints

Following factors are expected to restrain the global flavoxate hydrochloride tablets market growth over the forecast period. New medicines have been introduced in the market which belong to different chemical class than flavoxate hydrochloride which is expected to restrain growth of the flavoxate hydrochloride market. For instance, Merck & Co. Inc., received approval for Recabrio by U.S. Food and Drug Administration (FDA) in the year 2019. Recabrio is the combination of three different drugs i.e. Imipenem (antibacterial agent), Cilastatin (dehydropeptidase inhibitor), and Relebactam (beta lactamase inhibitor), a multifunctional drug useful for the treatment of urinary tract infection while flavoxate hydrochloride is a muscle relaxant.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/flavoxate-hydrochloride-tablets-market-3384

Global Flavoxate Hydrochloride Tablets Market Regional Analysis

North America is expected to hold dominant position in the global flavoxate hydrochloride tablets market over the forecast period, owing to the large customer base and increase in incidence of lower urinary tract dysfunction. Increasing prevalence of lower urinary tract dysfunction is expected to boost the North America flavoxate hydrochloride tablets market growth. For instance, according to the article from Neuroimmunology and Neuroinflammation, 2019, 291,000 individuals in the U.S.  were suffering from lower urinary tract dysfunction due to spinal cord injury.

According to the Arab Journal of Urology, 2019, in Europe 66% of women were suffering from lower urinary tract dysfunction mainly due to reasons such as nocturia, urgency, and urinary tract infections. According to the Hong Kong Medical journal, 2019, in Asia, around, 77.8% of men and 77.3% of women over the age of 40 suffer from mild degree of lower urinary tract symptoms. The above factors are expected to support the global flavoxate hydrochloride tablets market growth over the forecast period.

Global Flavoxate Hydrochloride Tablets Market Key Players

Some of the key players operating in the global flavoxate hydrochloride tablets market are Epic Pharma LLC, Perrigo Company PLC, Manus Aktteva Biopharma LLP, Recordati S.p.A, Taj Pharmaceuticals Ltd., Trumac Healthcare, Zhejiang CONBA Pharmaceutical co., ltd., Walter Bushnell, and Cipla Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3384

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Continuous Peripheral Nerve Block Catheter Market Opportunity Analysis-2027

 

A nerve block is the injection of local anesthetic near specific nerves that is administered for pain management during and after surgery. It can be used for surgery on the shoulder, elbow, forearm, wrist, hand, fingers, knee, leg, ankle, or foot.

Statistics:

North America region held dominant position in the global Continuous Peripheral Nerve Block Market in 2019, accounting for 42.9% share in terms of value, followed by Europe.

Global Continuous Peripheral Nerve Block Catheter Market: Drivers

Increasing number of total knee replacement surgeries is also expected to aid in growth of the global continuous peripheral nerve block catheter market over the forecast period. For instance, according to American Academy of Orthopedic Surgeons, by 2030, primary total joint replacement is projected to increase by 171% and primary total knee replacement is projected to increase by up to 189%, for a projected 635,000 and 1.28 million procedures, respectively, in the U.S.

Global Continuous Peripheral Nerve Block Catheter Market: Opportunities

Increasing prevalence of osteoarthritis (OA) resulting in demand for joint replacement procedures is also expected to boost growth of the market. For instance,  According to the study ‘Osteoarthritis in Europe: Impact on health status, work productivity and use of pharmacotherapies in five European countries’ that examined the impact of peripheral joint osteoarthritis across five European countries, UK (43.6%), France, (25.6%), Germany, (15.2%), Spain, (8.4%), and Italy (7.1%) recorded high prevalence of peripheral joint osteoarthritis, with majority of cases aging 55-74 years.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3399

Global Continuous Peripheral Nerve Block Catheter Market: Restraints

Lower accuracy and precession of CPNBC for nerve stimulation-based insertion is expected to hinder growth of the market. In CPNBC, vascular puncture is common and may result in significant bleeding, localized inflammation, local infection, and abscess formation.

Key Takeaways:

The Non-stimulating Catheter segment in the global continuous peripheral nerve block catheter market was valued at US$ 260.2 Mn in 2019 and is expected to reach US$ 430.1 by 2027 at a CAGR of 6.5% during the forecast period. The growth of the segment is attributed to increasing number of knee replacement surgeries in developing and developed economies during the forecasted period.

The Nerve Stimulation segment held dominant position in the global continuous peripheral nerve block catheter market in 2019, accounting for 62.0% share in terms of value, during the forecasted period. Increasing prevalence of osteoarthritis (OA) is anticipated to propel the growth of the segment during the forecasted period.

Market Trends

CPNBC are widely used with disposable infusion pumps for post-operative pain management at home. These pumps are available in different sizes and contain analgesic drug that infuses through the catheter.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/continuous-peripheral-nerve-block-catheter-market-3399

Peripheral nerve block catheter is recommended after orthopedic surgeries such as arthroplasty procedures of hip, knee and shoulder joint. CPNBC are also used along with CPM (Continuous Passive Motion) after a major orthopedic surgery to regain range of motion.

Global Continuous Peripheral Nerve Block Catheter Market: Competitive Landscape

Major players operating in the global continuous peripheral nerve block catheter market include, B. Braun Melsungen AG, Halyard Health, Inc., Ambu A/S, Epimed International Inc., Teleflex Incorporated, and Pajunk GmbH

Global Continuous Peripheral Nerve Block Catheter Market: Key Developments

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in October 2018, Teleflex Incorporated acquired Essential Medical, a privately-held medical device company.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3399

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737